Price, D. Et Al. 2022. No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators. RESPIROLOGY , 28-29.

Price, D., Henley, W., Carter, V., Skinner, D., Vella, R., Papi, A., ... Fabbri, L.(2022). No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators. RESPIROLOGY , 28-29.

Price, D. Et Al. "No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators," RESPIROLOGY , 28-29, 2022

Price, D. Et Al. "No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators." RESPIROLOGY , pp.28-29, 2022

Price, D. Et Al. (2022) . "No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators." RESPIROLOGY , pp.28-29.

@article{article, author={D. Price Et Al. }, title={No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators}, journal={RESPIROLOGY}, year=2022, pages={28-29} }